190 related articles for article (PubMed ID: 36923134)
1. Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use.
Grandits M; Grünwald-Gruber C; Gastine S; Standing JF; Reljic R; Teh AY; Ma JK
Front Plant Sci; 2023; 14():1126470. PubMed ID: 36923134
[TBL] [Abstract][Full Text] [Related]
2. Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques.
Rosenberg YJ; Lewis GK; Montefiori DC; LaBranche CC; Lewis MG; Urban LA; Lees JP; Mao L; Jiang X
PLoS One; 2019; 14(2):e0212649. PubMed ID: 30785963
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies.
Edwards JM; Heydarchi B; Khoury G; Salazar-Quiroz NA; Gonelli CA; Wines B; Hogarth PM; Kristensen AB; Parsons MS; Purcell DFJ
J Virol; 2021 Jun; 95(13):e0021921. PubMed ID: 33853957
[TBL] [Abstract][Full Text] [Related]
4. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
5. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
[TBL] [Abstract][Full Text] [Related]
6. Broadly neutralizing monoclonal antibodies for HIV prevention.
Miner MD; Corey L; Montefiori D
J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25829. PubMed ID: 34806308
[TBL] [Abstract][Full Text] [Related]
7. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
Gautam R; Nishimura Y; Gaughan N; Gazumyan A; Schoofs T; Buckler-White A; Seaman MS; Swihart BJ; Follmann DA; Nussenzweig MC; Martin MA
Nat Med; 2018 May; 24(5):610-616. PubMed ID: 29662199
[TBL] [Abstract][Full Text] [Related]
8. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses.
Berendam SJ; Styles TM; Morgan-Asiedu PK; Tenney D; Kumar A; Obregon-Perko V; Bar KJ; Saunders KO; Santra S; De Paris K; Tomaras GD; Chahroudi A; Permar SR; Amara RR; Fouda GG
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177194
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies toward Eradication of the HIV-1 Reservoir.
Mujib S; Liu J; Rahman AKMN; Schwartz JA; Bonner P; Yue FY; Ostrowski MA
J Virol; 2017 Aug; 91(16):. PubMed ID: 28592534
[TBL] [Abstract][Full Text] [Related]
10. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
[TBL] [Abstract][Full Text] [Related]
11. A novel anti-HIV-1 bispecific bNAb-lectin fusion protein engineered in a plant-based transient expression system.
Seber Kasinger LE; Dent MW; Mahajan G; Hamorsky KT; Matoba N
Plant Biotechnol J; 2019 Aug; 17(8):1646-1656. PubMed ID: 30729651
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.
Rao PG; Lambert GS; Upadhyay C
J Virol; 2023 Sep; 97(9):e0071023. PubMed ID: 37681958
[TBL] [Abstract][Full Text] [Related]
13. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.
Ko S; Park S; Sohn MH; Jo M; Ko BJ; Na JH; Yoo H; Jeong AL; Ha K; Woo JR; Lim C; Shin JH; Lee D; Choi SY; Jung ST
Exp Mol Med; 2022 Nov; 54(11):1850-1861. PubMed ID: 36319752
[TBL] [Abstract][Full Text] [Related]
14. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of a highly potent and near pan-neutralising anti-HIV monoclonal antibody expressed in tobacco plants.
Moore CM; Grandits M; Grünwald-Gruber C; Altmann F; Kotouckova M; Teh AY; Ma JK
Retrovirology; 2021 Jun; 18(1):17. PubMed ID: 34183026
[TBL] [Abstract][Full Text] [Related]
16. Potent
Bardhi A; Wu Y; Chen W; Li W; Zhu Z; Zheng JH; Wong H; Jeng E; Jones J; Ochsenbauer C; Kappes JC; Dimitrov DS; Ying T; Goldstein H
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794022
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
[TBL] [Abstract][Full Text] [Related]
19. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]